<DOC>
	<DOCNO>NCT01844310</DOCNO>
	<brief_summary>This study evaluate safety efficacy RAL-based regimen treatment-experienced patient resistant HIV infection</brief_summary>
	<brief_title>Raltegravir-based Antiretroviral Therapy Resistant HIV-1 Infection</brief_title>
	<detailed_description>In study , efficacy safety raltegravir ( RAL ) -based therapy assess . 300 treatment-experienced patient drug-resistant HIV randomize two arm ( 2:1 ) . Group A ( n=200 ) assign RAL-based regimen ( RAL+TDF+LPV/r ) .Group B ( n=100 ) assign current second-line regimen China ( 3TC+TDF+LPV/r ) . Both virological immunological profile response baseline week 4 , 8 , 12 , 24 , 36 , 48 evaluate . This study first large-scale , multicenter , randomize , prospective RAL-based therapy study China HIV/AIDs patient . The result provide prove practical antiviral therapy China resource-limiting country .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Age 1865 year 2 . HIV seropositive confirm western blot 3. take first line antiretroviral therapy one year one criterion list ( viral load patient meet criterion confirm PUMCH laboratory ) 1 . Viral load 400 copies/ml 2 . Viral rebound ( confirm HIV RNA 400 copies/ml virologic suppression ) 3 . When viral load monitor , patient experience immunologic failure meet least one criterion list enrol : CD4 count equal low baseline level firstline therapy , two occasion three month apart CD4 count 50 percentage fall ontreatment peak value persistent CD4 count level less 100 cells/μl oneyear antiretroviral therapy Previous use protease inhibitor Previous use integrase inhibitor Pregnancy breastfeed poor compliance drug interaction , opportunistic infection malignancy recruitment ; opportunistic infection within three month still unstable within 14 day prior recruitment HBsAg positive patient follow test result screen inclusion : WBC count &lt; 2000/μl , neutrophil count &lt; 1000/μl , Hb &lt; 9g/dl , platelet count &lt; 75000/μl , serum creatinine &gt; 1.5 ULN , transaminases alkaline phosphatase &gt; 3 ULN , total bilirubin &gt; 2 ULN , serum creatinine kinase &gt; 2 ULN CCr &lt; 60 ml/min Current intravenous drug use Severe neuropathy mental disorder history alcohol abuse unable withdrawal Severe peptic ulcer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>